Study: Pricey devices, diagnostics driving up healthcare costs; Romney's ad wrong on device tax;

 @FierceMedDev: Evidence is building that MRI scans can be safe for people with pacemakers or implanted defibrillators--via ReutersArticle | Follow @FierceMedDev

 @MarkHFierce: TAVI works well for some patients, a new study concludes--a boost for tech made by Edwards, Medtronic and others. Report | Follow @MarkHFierce

 @DamianFierce: OmniGuide pulled in $35M from OrbiMed to market its laser surgery devices. More | Follow @DamianFierce

> Pricey medical devices and diagnostic technologies are huge contributors to the increasing cost of inpatient care, according to a study. Article

> China will triple spending on medical devices, drugs, and hospital treatments to nearly $1 trillion by 2020, according to a new McKinsey & Co. report. Story

> BSD Medical ($BSDM)  has expanded the MicroThermX microwave ablation system into urban markets across the U.S., hiring new sales reps to expand use of the device. More

> Teleflex ($TFX) scored a three-year deal to put its respiratory devices in Premier healthcare alliance's 2,600 hospitals. News

> Twenty small-scale manufacturers in the state of Gujarat, India, are looking to bolster the local medtech industry by banding together to create a common medical device manufacturing unit, producing raw materials and components they all can use. Report

> Toshiba is boasting that its Aquilion Prime 160 CT scanner has proven effective in imaging patients with irregular heartbeats, something other devices struggle to do accurately. Item

> Nipro Diagnostics has signed a deal to integrate its TRUEresult blood glucose monitoring system with NextGen Healthcare's Ambulatory EHR, allowing users to access blood readings instantly. Story

> AdvaMed is accepting applications for its Medical Technology Veterans Program Boot Camp for Returning Heroes, a year-long initiative aimed to help military veterans find jobs in the medical technology industry. Release

Biotech News

 @FierceBiotech: Tech startup waltzes with wireless giant in Africa to expand mobile anti-drug counterfeiting system. Article | Follow @FierceBiotech

 @JohnCFierce: ArQule tanks after tox fears force a delay in Asian lung cancer study. News | Follow @JohnCFierce

 @RyanMFierce: Achillion M&A talk again post BMS setback with Hep C nuc, but I'm thinking after BMS' M&A debacle pharma won't be so trigger-happy with deals. More | Follow @RyanMFierce

> Hot M&A trend in biopharma spurs surge in insider trading cases. Story

> Strike three: Bad data bury Eli Lilly's late-stage schizophrenia drug. Article

> Boom times for the regulatory affairs profession. Item

> Big Pharma betting billions in high-stakes hunt for the next Lipitor. Report

Pharma News

 @FiercePharma: Primary-care sales reps may have a tough time seeing their docs, but cancer reps? Talk to the hand--PharmaTimesReport | Follow @FiercePharma

> Highly sought GSK plant project runs into local opposition. More

> SEC rounds up insider trading 'ring' around Sanofi's Chattem buyout. News

> FDA panel gives Humira a thumbs-up for colitis. News

Biomarkers News

> Genentech and academics spot colon cancer gene markers. More

> For glioma, it's all in the letters. Story

Drug Delivery News

> Proteonomix licenses out cells that deliver anti-cancer factors. More

> Silence is golden: U.K. RNAi player signs delivery pact with MiReven. Article

> Cisplatin liposomes cut side effects. Item

And Finally... In a TV ad, Mitt Romney says the 2.3% medical device tax rolled into the Affordable Care Act would tax the sale of wheelchairs, but FactCheck.org reports that wheelchairs are in face exempt from the charge. More

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.